$ENGN News

enGene Therapeutics Inc. (ENGN) Discusses Preclinical Data and Clinical Case Studies on Incorporating Surfactant Bladder Rinse into Treatment - Slideshow

enGene Highlights Surfactant-Enhanced Bladder Cancer Therapy Data and 2027 Update Path

enGene Therapeutics Inc. (ENGN) Discusses Preclinical Data and Clinical Case Studies on Incorporating Surfactant Bladder Rinse into Treatment Transcript

enGene to Host KOL Webinar on October 15, 2026

enGene Therapeutics Inc. (ENGN) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript

enGene Therapeutics: Slashing Cash Burn To Bring Their Asset To The Market

Citizens Reiterates Market Perform on enGene Therapeuticsto Market Perform

enGene Reports Third Quarter 2026 Financial Results and Provides Business Update

enGene Holdings Q3 EPS $(0.47) Misses $(0.43) Estimate

enGene to Participate in Upcoming Investor Conferences

enGene Eyes 2027 Approval as Detalimogene Targets Expanding Bladder Cancer Market

enGene Therapeutics Inc. (ENGN) Discusses Market Insights and Clinical Development in Non-Muscle Invasive Bladder Cancer Transcript

enGene Therapeutics Inc. (ENGN) Discusses Market Insights and Clinical Development in Non-Muscle Invasive Bladder Cancer - Slideshow

enGene to Host Virtual KOL Event to Discuss Emerging Non-Muscle Invasive Bladder Cancer (NMIBC) Market Insights, on August 11, 2026

enGene Focuses Board to Support Planned Upcoming Regulatory and Commercial Milestones

EnGene Therapeutics Appoints Michael Heffernan Board Chairman, Effective Immediately, Succeeding Richard Glickman

Morgan Stanley Downgrades enGene Therapeutics to Underweight

HC Wainwright & Co. Maintains Buy on enGene Therapeutics, Lowers Price Target to $4

enGene Reports Second Quarter 2026 Financial Results and Provides Business Update

EnGene Therapeutics Implements Workforce Reduction Of About 50% In June 2026; CFO Ryan Daws To Depart From Co, Effective July 15, 202